Ki67 index in intracranial ependymoma:: a promising histopathological candidate biomarker
Ki67 index in intracranial ependymoma:: a promising histopathological candidate biomarker
复制标题
DOI：
10.1111/j.1365-2559.2008.03065.x
复制
发表时间：
2008-07-01
期刊：
影响因子：
6.4
通讯作者：
Hainfellner, J. A.
中科院分区：
文献类型：
--
作者：
Preusser, M.;Heinzl, H.;Hainfellner, J. A.
目的：Ki67肿瘤细胞增殖指数是室管膜瘤患者的独立预后因素。将Ki67指数确认为组织病理学生物标记物的基本前提是该因子的可重复性以及不同观察者对其预后的影响(客观、临床和分析表现的证明)。为此，本研究的目的是系统分析Ki67指数对颅内室管膜瘤预后影响的观察者间和观察者内的一致性和可重复性。方法和结果：研究队列包含78例颅内室管膜瘤。在所有情况下，Ki67指数都是由四名有经验的观察员(EOS)和四名没有经验的观察员(IOS)使用手动热点方法进行评估的。对Ki67指数的评估有相当大的共识。与内部监督办公室相比，内部监督办公室之间的观察员一致性更高。对于每个观察者，生存分析显示低Ki67指数与有利的患者预后显著相关。结论：我们的数据显示，Ki67指数在颅内室管膜瘤中是一个可重复且可靠的预后因素，可被认为是一个有前途的组织病理学候选生物标记物。获得生物标记物的地位需要在前瞻性治疗试验的背景下进行进一步的翻译研究。
Aims: The Ki67 tumour cell proliferation index is an independent prognostic factor in ependymoma patients. Essential prerequisites for validation of the Ki67 index as a histopathological biomarker are the reproducibility of this factor and its prognostic influence by different observers (proof of objective clinical and analytical performance). To this end, the aim was to analyse systematically inter- and intraobserver agreement and reproducibility of the prognostic impact of the Ki67 index in intracranial ependymoma.Methods and results: The study cohort contained 78 cases of intracranial ependymoma. In all cases, the Ki67 index was assessed by four experienced observers (EOs) and by four inexperienced observers (IOs) using the manual hot-spot method. There was considerable agreement on Ki67 index assessment. There was higher observer agreement among EOs compared with IOs. For each observer, survival analysis showed significant association of low Ki67 index with favourable patient outcome.Conclusions: Our data show that the Ki67 index in intracranial ependymoma is a reproducible and robust prognostic factor and can be considered a promising histopathological candidate biomarker. Attainment of biomarker status requires further translational studies in the context of prospective therapeutic trials.